Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MARY ANN PICONE

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1295888030
CMS profile
911929
Location
TEANECK, NJ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$306,145.50

317 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Page 4 of 7; records 151–200 of 317 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MARY ANN PICONE

NPI 1295888030 · CMS profile ID 911929

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

TEANECK, NJ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 7; records 151–200 of 317 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1295888030?year=2025&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MARY ANN PICONE, NPI 1295888030, CMS profile ID 911929. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 7; records 151–200 of 317 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1295888030?year=2025&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). MARY ANN PICONE, NPI 1295888030, CMS profile ID 911929. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 7; records 151–200 of 317 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1295888030?year=2025&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
MARY ANN PICONE, NPI 1295888030, CMS profile ID 911929, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 7; records 151–200 of 317 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1295888030?year=2025&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

317 matching records · $306,145.50 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 317 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–200 of 317.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
TG Therapeutics, Inc. $3,712.5006/28/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1226252575 CMS
E.R. Squibb & Sons, L.L.C. $656.4606/26/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1184836199 CMS
E.R. Squibb & Sons, L.L.C. $120.2906/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184836201 CMS
GENZYME CORPORATION $25.4506/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233243591 CMS
EMD Serono, Inc. $595.0006/25/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1236867592 CMS
Genentech USA, Inc. $32.3506/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1211545069 CMS
Genentech USA, Inc. $166.9106/25/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1211545119 CMS
Amgen Inc. $3,300.0006/24/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1226921271 CMS
Genentech USA, Inc. $1,196.5006/24/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1211545058 CMS
Genentech USA, Inc. $192.6606/24/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1211545061 CMS
Genentech USA, Inc. $33.6006/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1211545082 CMS
Genentech USA, Inc. $416.0806/24/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1211545086 CMS
Genentech USA, Inc. $416.0806/24/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1211545110 CMS
Genentech USA, Inc. $10.0006/23/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1211545073 CMS
Genentech USA, Inc. $65.0006/23/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1211545107 CMS
Vanda Pharmaceuticals Inc. $15.9206/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1232994210 CMS
Amgen Inc. $124.9906/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228523078 CMS
Celgene Corporation $19.0306/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184836187 CMS
TG Therapeutics, Inc. $932.4206/13/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1226252587 CMS
TG Therapeutics, Inc. $3,712.5006/13/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1226252642 CMS
Biogen, Inc. $28.9206/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1208443913 CMS
Vanda Pharmaceuticals Inc. $6.1706/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1232994208 CMS
Amgen Inc. $2.6906/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227108588 CMS
Amgen Inc. $9.0006/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227108592 CMS
Novartis Pharmaceuticals Corporation $23.5906/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200668285 CMS
Vanda Pharmaceuticals Inc. $105.1006/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1232994204 CMS
Vanda Pharmaceuticals Inc. $4,650.0006/10/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1232994206 CMS
Genentech USA, Inc. $5.9306/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1211545014 CMS
Philips North America LLC $13.6106/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1232590470 CMS
Genentech USA, Inc. $3,630.0006/05/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1211545053 CMS
Genentech USA, Inc. $42.7006/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1211545104 CMS
Amgen Inc. $2,750.0006/03/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1226921295 CMS
Genentech USA, Inc. $14.3306/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1211545017 CMS
EMD Serono, Inc. $37.2705/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1236905127 CMS
Genentech USA, Inc. $216.5905/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1211545037 CMS
TG Therapeutics, Inc. $78.7605/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1226252776 CMS
TG Therapeutics, Inc. $79.1905/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1226252779 CMS
Amgen Inc. $101.8105/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228523070 CMS
EMD Serono, Inc. $19.7105/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1236920941 CMS
Celgene Corporation $18.5005/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184836179 CMS
Genentech USA, Inc. $50.0005/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1211545048 CMS
Amgen Inc. $19.9405/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228523066 CMS
TG Therapeutics, Inc. $1,250.8805/16/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1226252548 CMS
TG Therapeutics, Inc. $4,387.5005/16/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1226252609 CMS
Biogen, Inc. $150.0005/14/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1208335257 CMS
ABBVIE INC. $14.1705/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203618169 CMS
Philips North America LLC $18.6705/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1232590462 CMS
TG Therapeutics, Inc. $10.5905/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1226252517 CMS
TG Therapeutics, Inc. $3,712.5005/09/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1226252565 CMS
TG Therapeutics, Inc. $853.1805/09/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1226252621 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $222,254.62 463
PY2020 $116,828.70 138
PY2021 $174,252.41 221
PY2022 $228,926.99 286
PY2023 $211,940.94 287
PY2024 $235,960.41 296
PY2025 $306,145.50 317

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $190,656.92 21
PY2024 Principal investigator $98,076.28 21
PY2023 Principal investigator $46,232.90 12
PY2022 Principal investigator $127,941.04 25
PY2021 Principal investigator $169,756.59 17
PY2020 Principal investigator $347,593.31 11
PY2019 Recipient $536.00 1
PY2019 Principal investigator $296,737.94 20

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

21 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 GENZYME CORPORATION $9,950.00 12/08/2025 Non-covered Recipient Entity
Holy Name Medical Center
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226135964
Principal investigator 1 GENZYME CORPORATION $2,000.00 12/08/2025 Non-covered Recipient Entity
Holy Name Medical Center
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226135968
Principal investigator 1 TG Therapeutics, Inc. $15,275.00 11/30/2025 Non-covered Recipient Entity
Holyname Medical Center, inc.
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226200777
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,236.92 11/19/2025 Non-covered Recipient Entity
HOLY NAME MEDICAL CENTER
A Randomized, Open-label, Parallel-group, Non-inferiority Study Comparing Efficacy, Safety, and Tolerability of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis, Followed by Open-label Treatment With R No dispute reported 06/30/2026 1190308936
Principal investigator 1 TG Therapeutics, Inc. $3,550.00 11/01/2025 Non-covered Recipient Entity
Holyname Medical Center, inc.
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226200773
Principal investigator 1 TG Therapeutics, Inc. $11,250.00 11/01/2025 Non-covered Recipient Entity
Holyname Medical Center, inc.
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226200775
Principal investigator 1 TG Therapeutics, Inc. $21,700.00 10/06/2025 Non-covered Recipient Entity
Holyname Medical Center, inc.
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226200771
Principal investigator 1 TG Therapeutics, Inc. $11,250.00 09/30/2025 Non-covered Recipient Entity
Holyname Medical Center, inc.
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226200747
Principal investigator 1 EMD Serono, Inc. $345.00 09/24/2025 Non-covered Recipient Entity
Advarra, Inc.
Effectiveness of Switching to Cladribine Tablets in Multiple Sclerosis Patients with High Disease Activity or Disease Breakthrough in a US Real-World Population (HDA Switch Study) No dispute reported 06/30/2026 1240118129
Principal investigator 1 F. Hoffmann-La Roche AG $3,803.00 09/22/2025 Non-covered Recipient Entity
HOLY NAME MEDICAL CENTER INC
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211612978
Principal investigator 1 TG Therapeutics, Inc. $10,200.00 08/31/2025 Non-covered Recipient Entity
Holyname Medical Center, inc.
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226200745
Principal investigator 1 GENZYME CORPORATION $35,212.00 08/04/2025 Non-covered Recipient Entity
Holy Name Medical Center
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226135919
Principal investigator 1 TG Therapeutics, Inc. $7,875.00 07/31/2025 Non-covered Recipient Entity
Holyname Medical Center, inc.
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226200743
Principal investigator 1 F. Hoffmann-La Roche AG $241.00 07/23/2025 Non-covered Recipient Entity
HOLY NAME MEDICAL CENTER INC
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211612975
Principal investigator 1 EMD Serono, Inc. $21,196.00 06/23/2025 Non-covered Recipient Entity
Holy Name Medical Center
Effectiveness of Switching to Cladribine Tablets in Multiple Sclerosis Patients with High Disease Activity or Disease Breakthrough in a US Real-World Population (HDA Switch Study) No dispute reported 06/30/2026 1240118353
Principal investigator 1 EMD Serono, Inc. $1,345.00 05/22/2025 Non-covered Recipient Entity
Advarra, Inc.
Effectiveness of Switching to Cladribine Tablets in Multiple Sclerosis Patients with High Disease Activity or Disease Breakthrough in a US Real-World Population (HDA Switch Study) No dispute reported 06/30/2026 1240118121
Principal investigator 1 F. Hoffmann-La Roche AG $8,782.00 04/25/2025 Non-covered Recipient Entity
HOLY NAME MEDICAL CENTER INC
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211612971
Principal investigator 1 EMD Serono, Inc. $1,280.00 03/24/2025 Non-covered Recipient Entity
Advarra, Inc.
Effectiveness of Switching to Cladribine Tablets in Multiple Sclerosis Patients with High Disease Activity or Disease Breakthrough in a US Real-World Population (HDA Switch Study) No dispute reported 06/30/2026 1240118126
Principal investigator 1 GENZYME CORPORATION $16,276.00 02/24/2025 Non-covered Recipient Entity
Holy Name Medical Center Found
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226158050
Principal investigator 1 GENZYME CORPORATION $7,649.00 02/24/2025 Non-covered Recipient Entity
Holy Name Medical Center Found
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226158056
Principal investigator 1 F. Hoffmann-La Roche AG $241.00 01/22/2025 Non-covered Recipient Entity
HOLY NAME MEDICAL CENTER INC
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211612966